Yazar "Türkçüer, İbrahim" seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • [ X ]
    Öğe
    DNA methylation profiles in pneumonia patients reflect changes in cell types and pneumonia severity
    (Taylor & Francis Inc, 2022) Morselli, Marco; Farrell, Colin; Montoya, Dennis; Gören, Tarik; Sabırlı, Ramazan; Türkçüer, İbrahim; Kurt, Özgür
    Immune cell-type composition changes with age, potentially weakening the response to infectious diseases. Profiling epigenetics marks of immune cells can help us understand the relationship with disease severity. We therefore leveraged a targeted DNA methylation method to study the differences in a cohort of pneumonia patients (both COVID-19 positive and negative) and unaffected individuals from peripheral blood. This approach allowed us to predict the pneumonia diagnosis with high accuracy (AUC = 0.92), and the PCR positivity to the SARS-CoV-2 viral genome with moderate, albeit lower, accuracy (AUC = 0.77). We were also able to predict the severity of pneumonia (PORT score) with an R-2 = 0.69. By estimating immune cellular frequency from DNA methylation data, patients under the age of 65 positive to the SARS-CoV-2 genome (as revealed by PCR) showed an increase in T cells, and specifically in CD8+ cells, compared to the negative control group. Conversely, we observed a decreased frequency of neutrophils in the positive compared to the negative group. No significant difference was found in patients over the age of 65. The results suggest that this DNA methylation-based approach can be used as a cost-effective and clinically useful biomarker platform for predicting pneumonias and their severity.
  • Küçük Resim
    Öğe
    A hypertrophic spinal pachymeningitis patient with Factor V Leiden (G1691A), MTHFR C677T, MTHFR A1298C, PAI- 1 4G-5G, Glycoprotein IIIa L33P gene mutations
    (Cureus Inc, 2022) Civlan, Serkan; Harvey, Cemre; Herek, Duygu; Türkçüer, İbrahim; Sabırlı, Ramazan; Pellegrini, Matteo; Köseler, Aylin
    Hypertrophic pachymeningitis (HP) is a rare clinical entity of diverse etiology, characterized by a chronic inflammation that causes dura thickening. Reports of Idiopathic hypertrophic cranial pachymeningitis (IHCP) were related to infections, trauma, tumors, and rheumatologic conditions. It was first described by Charcot and Joffroy regarding spinal meninges in 1869. HP has three stages; progressive radicular symptoms begin first, then muscle weakness and atrophy start. Findings such as paraplegia, loss of bladder and bowel control, and respiratory distress caused by intercostal and diaphragmatic denervation are considered the third stage of the disease. Especially in the cranial form of the disease, nerve ischemia and various cranial neuropathic findings may occur. Factor V Leiden (G1691A), MTHFR C677T, MTHFR A1298C, and PAI-1 4G-5G gene mutation analysis were measured with an ABI Prism. In this case report, the authors present a case of hypertrophic mutations pachymeningitis with Factor V Leiden (G1691A), MTHFR C677T, MTHFR A1298C, PAI-1 4G-5G, Glycoprotein IIIa L33P gene. In conclusion, we report a case of HP with Factor V Leiden (G1691A), MTHFR C677T, MTHFR A1298C, PAI-1 4G-5G, and Glycoprotein IIIa L33P gene mutations. We emphasize that the identification of pachymeningitis can be easily bypassed with the application of limited laboratory techniques. As in this case report, we think that these mutations should be analyzed in patients diagnosed with pachymeningitis.
  • Küçük Resim
    Öğe
    Sürfaktan protein D düzeyleri ile COVID-19 klinik şiddeti arasindaki ilişkinin değerlendirilmesi: bir vaka kontrol çalışması
    (Pamukkale Üniversitesi, 2023) Karslı, Emre; Sabırlı, Ramazan; Gören, Tarık; Kemancı, Aykut; Karış, Denizhan; Türkçüer, İbrahim; Kurt, Özgür
    Amaç: Serum surfaktan protein D (SP-D) vücutta viral enfeksiyona karşı koruma, bakteriyel ve fungal klirens,apoptotik hücrelerin temizlenmesi ve inflamasyonun baskılanması gibi roller oynar. Bu çalışma, SP-D düzeyi ilekoronavirüs hastalığı (COVID-19) şiddeti arasındaki ilişkiyi incelemeyi amaçlamaktadır.Gereç ve yöntem: Çalışmaya 80 hasta (30 hafif hastalığı ve 50 ağır/kritik COVID-19) ve 50 sağlıklı gönüllü dahiledildi. Serum örneklerinde SP-D seviyeleri ELISA ile analiz edildi.Bulgular: SP-D düzeyi ortanca değeri hafif hastalıkta 2,47 (1,67-7,79) ng/ml, ağır/kritik hastalık gruplarında5,65 (3,09-16,55) ng/ml iken, sağlıklı control grubunda 2,89 (10,8-6,24) ng/ml olarak bulundu. Ağır/kritik hastalıkgrubu hem hafif hastalık hem de kontrol grubu ile karşılaştırıldığında SP-D düzeylerindeki farklılıklar istatistikselolarak anlamlı bulundu (sırasıyla p=0,007 ve 0,001). ROC analizi, hafif COVID-19 hastalığı hastalarına kıyaslaşiddetli/kritik COVID-19 hastalarında serum SP-D seviyeleri için eğri altında kalan alan daha yüksek saptandı(AUC=0.691, %95 CI=0,56-0.822; p=0,004). Ayrıca, ağır/kritik hastaları saptamak için SP-D düzeyleri 2,44 ng/ml düzeyinde (p=0,004) %86 duyarlı ve %51,6 özgül saptandı.Sonuç: SP-D seviyeleri, COVID-19 hastaları için klinik şiddeti ve prognozu tahmin etmede faydalıdır. SP-D,klinik şiddeti ve prognozu tahmin etmek için değerli bir biyobelirteçtir.